Combination therapy 'reduces risk of vascular events' in PAD

A secondary trial analysis shows low-dose rivaroxaban plus aspirin benefit high-risk patients with lower extremity PAD, authors say

High-risk patients with symptomatic peripheral artery disease (PAD) of the legs are less likely to experience major vascular events if they are treated with a combination of rivaroxaban and aspirin versus aspirin alone, a secondary analysis of clinical trial results suggests.

man with a below the knee amputation

The subanalysis was of a previously reported subgroup of patients with symptomatic lower extremity PAD enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies Study (COMPASS), which included 602 centres in 33 countries from